Group 1 - The Hong Kong stock market for innovative drugs experienced a decline, with the Hong Kong Stock Connect Innovative Drug ETF (520880) dropping by 2%, and major stocks like CSPC Pharmaceutical, China Biologic Products, and Hansoh Pharmaceutical falling over 2% [1] - The market is expected to see a traditional surge during the Chinese New Year holiday, with an average increase of 2% since 2021 [1] - CICC highlights four key sectors in the A-share market: dividends, internet, innovative drugs, and new consumption, which are considered to have long-term investment value [1] Group 2 - Chinese innovative drugs continue to gain traction internationally, with significant business development (BD) deals, including a partnership between Innovent Biologics and Eli Lilly worth up to $8.85 billion [2] - In January, CSPC Pharmaceutical announced a partnership with AstraZeneca valued at up to $18.5 billion, showcasing the global competitiveness of Chinese innovative drugs [2] Group 3 - The Chinese innovative drug sector is entering a commercialization phase, with over 70% of innovative drug companies reporting revenue growth, and companies like BeiGene achieving revenues exceeding 36 billion yuan [3] - Leading companies are starting to achieve profitability, with firms like Innovent Biologics and Rongchang Biologics reaching annual breakeven, and Elysium achieving over 2 billion yuan in net profit [3] - Open Source Securities expresses optimism about the innovative drug sector and its supply chain, as well as emerging industries like AI and biomanufacturing [3] Group 4 - The Hong Kong pharmaceutical sector has adjusted for nearly two quarters, presenting an attractive investment opportunity, particularly through ETFs for efficient capital allocation [3] - The Hong Kong Stock Connect Innovative Drug ETF (520880) focuses on innovative drug R&D companies, with the top ten holdings accounting for over 73% of the portfolio [3]

2月11日，易思维（杭州）科技股份有限公司登陆上交所科创板。至此，科创板上市公司总数达到 604家。 分行业看，集成电路、生物医药行业景气度明显回升。其中，集成电路产业受人工智能等新兴应用 需求拉动，延续较高景气度。87家公司披露业绩情况显示，合计净利润同比增加约99.49亿元，57家公 司业绩预增或扭亏为盈。 创新药行业则凭借商务拓展交易活跃、出海提速，商业化进程显著加快，招采回暖推动制药类公司 业绩回升。数据显示，26家创新药公司合计实现净利润增加14.49亿元，已披露营业收入的18家公司合 计实现营收241.57亿元，同比增长34.9%。 作为中国"硬科技"企业聚集地，科创板的板块产业图谱与现代化产业体系建设同向而行，尤其是在 新一代信息技术、生物医药、高端装备制造等战略性新兴产业领域，已形成"链主引领、上下协同"的发 展格局。 与此同时，板块业绩成长韧性凸显。截至2月9日，科创板已有391家公司以业绩预告或快报形式披 露2025年度预计业绩，其中近六成净利润实现同比增长。 "科创板上市公司已超过600家，这不仅是一个数量里程碑，它标志着这块'试验田'已茁壮成长为中 国硬科技创新的战略基座与资本市场改革 ...

Core Viewpoint - SHP2 inhibitors are emerging as a significant target for cancer treatment, with rapid development in the industry, particularly in China, which is becoming a notable player in the global market [1][6][9]. Industry Overview - SHP2, a protein tyrosine phosphatase, plays a crucial role in regulating various cellular functions, including growth, differentiation, and oncogenic transformation [2][6]. - The global market for SHP2 inhibitors is projected to start existing from 2027, reaching approximately $329 million by 2029, and is expected to grow to $4.821 billion by 2033 [1][7][9]. Market Size - The Chinese SHP2 inhibitor market is anticipated to grow to $206 million by 2029 and reach $784 million by 2033 [9][10]. Industry Chain - The SHP2 inhibitor industry chain includes upstream components such as protein reagents, specific antibodies, small molecule building blocks, testing kits, and experimental models; midstream involves drug research and production; downstream consists of large oncology specialty hospitals and comprehensive hospital oncology departments [11][12]. Development Environment - Recent policies in China have been implemented to encourage the pharmaceutical industry, particularly in the development and production of innovative drugs, including cancer therapies, by shortening clinical application and approval times [13][14]. Competitive Landscape - Major companies in the SHP2 inhibitor space include Innovent Biologics, CanSino Biologics, Junshi Biosciences, and others, with significant progress in developing SHP2 inhibitors, although no drugs have yet been approved for commercialization [15][16]. - Notable companies include: - **QinHao Pharmaceutical**: Focused on developing innovative candidates targeting the RAS signaling pathway, with its lead candidate GH21 in Phase II clinical trials [15][16]. - **Nuocheng Jianhua**: Known for its BTK inhibitor, it is also developing a new SHP2 inhibitor, ICP-189, in collaboration with ArriVent Biopharma [16][17]. Future Outlook - The SHP2 inhibitor sector is one of the hottest areas in pharmaceutical research, with significant advancements in the development of allosteric inhibitors and ongoing clinical trials showing promising results [17][18].

2025年，沪市公司经营韧性与结构亮点进一步显现，在"质"与"量"的双重维度上，助力中国经济破浪前 行。数据显示，截至2月9日，271家沪市主板公司发布2025年业绩预告，其中168家预增、85家预计扭 亏。391家科创板公司以业绩预告或快报形式披露了2025年业绩情况，近六成公司预计净利润实现同比 增长，其中39家预计净利润同比倍增、51家预计扭亏为盈。 一幅稳增长、优结构的沪市公司全年发展图景徐徐展开。记者关注到，业绩突出的公司主要集中在有色 金属、电子等行业。有色金属受产品价格与产销量共同驱动，电子行业在AI需求带动下维持较快增 长。与此同时，一批龙头公司预计盈利规模仍处于高位，持续发挥沪市主板"压舱石"作用。 有色金属行业发展尽显韧性 2025年，在全球地缘政治摩擦多发和主要经济体降息预期的推动下，黄金的避险与货币属性愈加显现， 黄金价格屡创新高，直接增厚了拥有巨量黄金储备企业的利润。 有色行业规模以上企业工业增加值增长6.9%，高于全国规上工业增加值增速1.0个百分点，十种有色金 属产量首次突破8000万吨大关。规模以上企业实现利润总额5284.5亿元，同比增长25.6%，创下历史新 高。下游新兴产 ...

本文字数：2754，阅读时长大约4分钟 作者 | 第一财经 黄思瑜 2月10日，随着新股电科蓝天（688818.SH）上市，科创板上市公司总数达到603家，总市值达到11.44万 亿元。 2026.02.10 截至目前，科创板逾390家公司以业绩预告或快报形式披露了2025年度预计业绩情况，占板块公司总数 的超六成；另有1家公司披露了科创板2025年度首份年报。从细分行业表现看，集成电路、生物医药行 业景气度回升。 科创综指为观察科创板整体情况和发展态势提供了全局性的视角。截至2月10日，科创综指样本数量达 580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发布时提升15.1%。 东吴证券首席经济学家、研究所联席所长芦哲对第一财经称，预期未来3～5年，科创板总市值有望翻 倍，科创综指将同步成长为"万亿级产品规模、千亿级日成交"的核心宽基指数，不仅与沪深300、创业 板指并驾齐驱，更可能率先完成"本土指数—跨境ETF—全球定价"的三级跳，成为中国科技创新实力对 外展示的"首张名片"。 391家公司"交卷"，六成预增 目前，科创板上市公司数量合计603家，包括61家未盈利企业、9家特殊 ...

Core Viewpoint - The upcoming Chinese New Year holiday will lead to a 10-day market closure for A-shares, while Hong Kong stocks (H-shares) will continue trading, raising questions about whether H-shares can perform independently during this period. The recent adjustments in H-shares, combined with the surge in AI applications, prompt an analysis of whether the market has reached a correction point [1][3]. Market Trends - Historically, the Hang Seng Index has shown an 82% probability of rising in the three trading days before the Spring Festival, with a 40%-60% chance of increasing after the holiday. The correlation between H-shares and A-shares has strengthened, while the correlation with U.S. stocks has weakened, suggesting a potential for passive upward movement in H-shares [3]. Sector Performance - The Hang Seng Technology Index has seen significant performance metrics, with an average increase of 72.7% from Christmas to the Spring Festival. The average increase for the Hang Seng Index during the same period is 3.8% [4]. Investment Opportunities - The recent pullback in H-shares has made valuations more attractive, with expectations of a rebound. The Hang Seng Technology Index's price-to-earnings (P/E) ratio is currently at 24.5, which is below the historical average, indicating a favorable entry point for investors [7][8]. Innovation and Drug Development - Significant partnerships in the biotech sector, such as the collaboration between Innovent Biologics and Eli Lilly, highlight the potential for innovation in the pharmaceutical industry. This partnership includes a $350 million upfront payment and potential milestone payments totaling up to $8.5 billion [9]. Consumer Sector Dynamics - As the Spring Festival approaches, consumer activity is expected to rise, particularly in sectors like gold retail and hospitality. Government policies aimed at boosting consumption are likely to enhance market sentiment and drive growth in the consumer sector [11]. Dividend Strategies - In a low-interest-rate environment, dividend strategies are becoming increasingly attractive. The dividend yield for H-shares remains higher compared to A-shares, making them a compelling option for investors seeking stable returns [12][13]. Automotive Sector Growth - The automotive sector is poised for growth due to supportive policies and technological advancements in smart driving. The introduction of new policies for electric vehicle purchases is expected to stimulate demand, while advancements in autonomous driving technology present further opportunities [14][15].

自2025年1月20日正式发布以来，上证科创板综合指数(简称"科创综指")已平稳运行一年。作为刻画科 创板"全景图"的指数，科创综指在表征市场整体表现与引导长期资金配置方面的作用日益凸显。 数据显示，截至2月10日，科创综指样本数量达580只，市值覆盖度超过90%，总市值高于100亿元的科 创综指成分股权重占比较发布时提升15.1%，成长效应显著。 科创板自设立以来，先后推进试点注册制、"科创板八条""科创板1+6"三轮系统性改革，着力提高资本 市场制度包容性、适应性。截至2月10日，科创板累计支持61家未盈利企业、9家特殊股权架构企业、7 家红筹企业、23家第五套标准企业上市。未盈利上市企业中22家上市后成功盈利"摘U"。 科创板公司坚持创新驱动发展，持续加大创新要素投入力度，创新成果积极涌现。2025年前三季度，科 创板公司研发投入总额达1328.64亿元，是板块净利润的2.7倍；研发投入占营业收入比例中位数为 12.5%，远高于A股其他板块。 并购重组市场日益活跃，自"科创板八条"发布以来，板块新增并购交易170余单、金额超900亿元，交易 达成率近七成；2025年以来发布重大资产重组39单，数量超过前 ...

大河财立方记者 王宇 文 2月10日，科创板又迎来新兵电科蓝天，科创板上市公司总数目前已达603家。 大河财立方记者从上交所获悉，推出一年来，科创综指的市场关注度持续提升。截至2026年2月10日， 科创综指样本数量达580只，市值覆盖度超过90%，总市值高于100亿元的科创综指成份股权重占比较发 布时提升15.1%，成长效应显著。 据了解，科创综指已成为与上证指数、深证成指、创业板指并列的A股四大核心宽基指数，为境内外投 资者观测和分享中国新质生产力发展红利提供了重要工具。 科创综指涨幅达约63% 自2025年初发布以来，科创综指走势呈现出稳步向上的特征。其定位是覆盖科创板全市场的综合指数， 板块市值覆盖度超过90%，可以说是分享科创板公司成长发展成果的有力指标。 截至2026年2月10日，指数涨幅达到约63%。指数发布以来受到投资者的广泛认可，相关产品布局迅速 完善，已形成包括ETF、联接基金、增强型产品在内的完整产品链条，为各类投资者分享新质生产力发 展红利提供了高效、便捷的工具。 截至2026年2月9日，境内已有49家基金管理人推出共81只科创综指指数基金，场内外合计规模达258亿 元。上交所上市科创 ...

Group 1 - The Sci-Tech Innovation Board Composite Index (Sci-Tech Index) has been operating smoothly for one year since its official release on January 20, 2025, and has become a key tool for investors to observe and share the dividends of China's new productive forces [2] - As of February 10, 2025, the Sci-Tech Index covers 580 samples with a market capitalization coverage exceeding 90%, and the weight of constituent stocks with a total market value above 10 billion yuan has increased by 15.1% since its release [2] - The index has gained recognition among investors, with a total of 49 fund managers launching 81 index funds related to the Sci-Tech Index, achieving a combined scale of 25.8 billion yuan as of February 9, 2025 [4] Group 2 - The Sci-Tech Board has gathered over 600 companies, with the latest addition being the listing of Yuhang Power on February 10, 2025, marking it as the 603rd listed company [5] - The total R&D investment of Sci-Tech Board companies reached 132.864 billion yuan in the first three quarters of 2025, which is 2.7 times the net profit of the board, with a median R&D investment ratio of 12.5% of operating income, significantly higher than other A-share sectors [5] - As of February 9, 2025, 391 companies on the Sci-Tech Board have disclosed their expected performance for 2025, with over 60% of them reporting a year-on-year increase in net profit [6] Group 3 - The integrated circuit and biopharmaceutical industries are experiencing a recovery in prosperity, with 87 companies in the integrated circuit sector expected to see a combined net profit increase of approximately 9.949 billion yuan due to demand from emerging applications like artificial intelligence [7] - In the innovative drug sector, 26 companies are projected to increase their net profit by 1.449 billion yuan in 2025, with 18 companies reporting a total revenue of 24.157 billion yuan, reflecting a year-on-year growth of 34.9% [7]

Core Insights - The Science and Technology Innovation Board (STAR Market) has welcomed a new company, Electric Science and Technology Blue Sky, bringing the total number of listed companies to 603, highlighting its role as a hub for "hard technology" enterprises in China [2] - The STAR Market Composite Index has gained significant attention, with a sample size of 580 stocks and a market capitalization coverage exceeding 90%, indicating a notable growth effect [2][3] - Nearly 60% of STAR Market companies have reported a year-on-year increase in net profit, with 39 companies experiencing a substantial growth of over 100% [3] STAR Market Overview - The STAR Market is characterized by a development pattern of "chain leader guidance and upstream-downstream collaboration," particularly in strategic emerging industries such as new-generation information technology, biomedicine, and high-end equipment manufacturing [2] - The STAR Market Composite Index has become one of the four core broad-based indices in A-shares, providing a vital tool for domestic and international investors to observe and share in the dividends of China's new productive forces [2] Performance and Growth - As of February 9, 2026, 391 companies on the STAR Market have disclosed their expected performance for 2025, with over 60% of them showing a year-on-year increase in net profit [3] - The total R&D investment of STAR Market companies reached 132.864 billion yuan in the first three quarters of 2025, which is 2.7 times the net profit of the sector, with a median R&D investment ratio of 12.5% of operating income, significantly higher than other A-share sectors [3] Reform and Development - The STAR Market has undergone three rounds of systematic reforms aimed at enhancing the inclusiveness and adaptability of the capital market, supporting various types of companies, including unprofitable and special equity structure enterprises [4] - Since the introduction of the "STAR Market Eight Articles," over 170 new merger and acquisition transactions have been recorded, totaling more than 90 billion yuan, with a transaction completion rate of nearly 70% [5] Index and Product Ecosystem - The STAR Market Composite Index has shown a steady upward trend since its launch, with an increase of approximately 63% as of February 10, 2026 [6] - A complete product chain has been established, including ETFs, linked funds, and enhanced products, with 49 fund managers launching a total of 81 STAR Market Composite Index funds, achieving a combined scale of 25.8 billion yuan [6]